Kornimate/medical-research-clean huggingface dataset:
selective internal radiation therapy (sirt) in patients with unresectable colorectal cancer liver metastases who failed prior intraarterial pump chemotherapy

Conditions: Colon Cancer; Rectal Cancer

Summary: this study is being done with a new therapy called "selective internal radiation therapy" (known as sirt). radiation is an effective treatment for destroying tumors. it is widely used in cancer treatment. however, radiation can harm normal tissue. sir-spheres are tiny plastic beads. they contain a radioactive agent called yttrium-90. these beads can be delivered through a small tube inserted into the blood vessel that goes directly to the tumor. the radiation goes directly to the tumor. this spares healthy parts of your liver.


Eligibility criteria:
inclusion criteria: * histologic confirmation of colorectal cancer. * unequivocal imaging of hepatic metastases. * dominant liver metastases. (small amount extrahepatic disease allowed.) * unresectable liver metastases. * liver metastases non-eligible for, or progressed after ablation * failed prior hac. * ecog performance status 0 - 1 * wbc \> or = to 1.5 x 109/l * platelets \> or = to 50 x 109/l * creatinine ≤ 1.5 mg/dl * bilirubin ≤ 1.5 mg/dl * age \> or = to 18 years * female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active, must agree to use an acceptable method of contraception. * male patients must be surgically sterile, or if sexually active, must agree to use an acceptable method of contraception. * life expectancy of at least 3 months without any active treatment. * no chemotherapy regimen administration for at least 4 weeks prior to sirt administration exclusion criteria: * evidence of severe cirrhosis (childs b and c), portal hypertension with gastroesophageal varices and liver failure as determined by clinical, radiologic or laboratory assessment. * previous radiotherapy delivered to the liver. * pregnant or breast-feeding. * any of the following are contraindications to the use of yttrium-90 microspheres, and are therefore exclusion criteria: * with a tc-99m macroaggregated albumin (maa) hepatic arterial perfusion scintigraphy that shows any disposition to the gastrointestinal tract that cannot be corrected by angiographic and embolization techniques. * with more than 20% shunting of blood to the lungs as estimated in the lung scintigram performed after the intraarterial injection of tc maa. radiation pneumonitis has been seen in patients receiving doses of yttrium-90 greater than 30 gy in a single treatment. this corresponds to the shunt over 20% presence of vascular abnormalities, bleeding diathesis, making catheterization of the hepatic artery contraindication.

Keywords: colon liver rectum sir-spheres 09-030
tcm constitution, pattern types, and disease factors in primary lung cancer.

Conditions: Medicine, Chinese Traditional; Body Constitution; Syndrome; Risk Factors

Summary: recently, tcm has played an important role in adjuvant therapy for lung cancer. tcm treatment is based on pattern identification, and constitution theory is also used as a tool for tcm to predict the disease progression. although there have been many researchs related to the pattern identification and constitution of lung cancer, in view of the problems and limitations, further research on lung cancer patients in taiwan is needed. this study aims to explore the correlation between tcm constitution, pattern identification, and other related factors in patients with primary lung cancer in taiwan, hoping to reveal the disease characteristics of lung cancer in tcm theory. this study intends to interview subjects through attending physicians in the thoracic ward and outpatient clinic of the cmuh from november 20th, 2023 to may 19th , 2025, and the subjects will be included in this study after the researchers ask the subjects for consent. this study will collect the demographic data of the subjects (sex, age, bmi, smoking history) and disease-related clinical data (tumor stage, pathological type, gene mutation, tumor markers, other comorbidities), and the investigator will ask about the subjects' signs according to the constitution in chinese medicine questionnaire (ccmq) , ask the subjects' symptoms according to the pattern identification table, obtain the data to analyze their distribution by descriptive statistics, and then analyze the correlation between them by analysis of variance and chi-square test.


Eligibility criteria:
inclusion criteria: * patients diagnosed with primary lung cancer. * age greater than 18 years and less than 100 years. * after explanation, they agree to join this study and voluntarily sign the subject consent form, and can understand the content of the questionnaire. exclusion criteria: * pregnant women. * severe mental illness that affects the response to the questionnaire. * has been treated (e.g., surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, etc.). * concomitant with other uncured primary malignancies. * patients with other serious primary diseases (such as: liver and kidney dysfunction, hematolymphatic system diseases, etc.). * severe respiratory diseases that are not lung cancer (e.g. primary emphysema, interstitial fibrosis, etc.) .
hot snare versus hot snare polypectomy with saline injection for colorectal polyps

Conditions: Polyp of Large Intestine

Summary: the complete removal of colorectal polyp is required to prevent tumor recurrence and development of potential interval cancers. however, several studies have shown high incomplete resection rate in endoscopic removal of neoplastic colorectal polyps larger than 5 mm. the polypectomy techniques using hot snare are usually used for the removal of these polyps. however, the optimal technique for complete resection of these polyps is unknown. there are few data comparing hot snare polypectomy with hot snare polypectomy after saline injection for complete resection of colorectal polyps (5mm or larger). the aim of this study is to compare hot snare polypectomy with hot snare polypectomy after saline injection for removal of 5-10mm sized colorectal polyps.


Eligibility criteria:
inclusion criteria: * patients over the age of 30 * 5\~10mm sized colorectal polyps * informed consent exclusion criteria: * inflammatory bowel diseases (crohn's disease, or ulcerative colitis) * patient undergoing antiplatelets (aspirin, clopidogrel and others) or anticoagulant therapy * asa class iii or more * any condition which, in the opinion of the investigator, places the patient at unacceptable risk if he/she were to participate in the study

Keywords: neoplastic colorectal polyp hot snare polypectomy hot snare polypectomy after saline injection
tunisian clinical registry on hypoparathyroidism and pseudo-hypoparathyroidism

Conditions: Hypoparathyroidism; Pseudo Hypoparathyroidism

Summary: observational, multicenter, national, cross-sectional study aiming to describe the epidemiological clinical, biological and therapeutic profile of patients suffering from defect in secretion (hypoparathyroidism) or action (pseudo-hypoparathyroidism) of parathyroid hormone.

endocrinologists from both sectors (public and private) are participating in the study. data will be captured electronically by dacima clinical suite, according to fda 21 cfr part 11 (food and drug administration 21 code of federal regulations part 11), hipaa (health insurance portability and accountability act) \& ich (international conference on harmonisation) requirements.

Eligibility criteria:
inclusion criteria: * hypoparathyroidism defined by low serum calcium \< 2.2 mmol/l (\< 88 mg/l) associated with inadequate pth (low or normal) and normal creatinine exclusion criteria: * cervical surgery \< 6 months. * transient (neonatal, etc.) or functional (dysmagnesemia, etc.) hypoparathyroidism. * other causes of hypocalcemia: vitamin d deficiency, chronic renal failure, etc. * familial hypocalcemia hypercalciuria. * pseudo-pseudo-hypoparathyroidism.

Keywords: hypoparathyroidism pseudo hypoparathyroidism clinical registry endocrinology parathyroid gland
a research study to examine cutaneous allodynia and cluster headache

Conditions: Cluster Headache

Summary: this is a research study examining cutaneous allodynia and cluster headaches. cutaneous allodynia means the feeling of pain or unpleasant sensation when normally non-painful stimuli (e.g. light touch) are applied to the skin. many studies have been performed looking at the presence of cutaneous allodynia in patients with migraines; however, few studies have examined it in cluster headache patients. there is still much to be learned about the brain and how it functions if the investigators are to understand the underlying causes of cluster headache. it is important to explore cutaneous allodynia in cluster headache as it may help guide physicians with the care of these individuals. sixty patients will be screened for this study. thomas jefferson university is the only center enrolling patients in this research study.


Eligibility criteria:
inclusion criteria: * male and female patients aged 18-75, inclusive * diagnosis of cluster headache, episodic or chronic. * patients with episodic ch can be either in active cluster period or not. * ability to read and understand an informed consent form, where the study protocol is described. exclusion criteria: * patients with abnormal sensory findings on examination, or any known neurological disease that may affect skin sensation (peripheral neuropathy, multiple sclerosis, stroke, etc). * patients who are cognitively impaired, as determined by investigator * patients with significant psychiatric disorder that may affect their understanding of the study protocol and/or their cooperation with the investigators. * patients who had taken an acute pain medication within 24 hours prior to allodynia testing. * patients with skin diseases that may cause abnormal skin sensation. * patients who had been treated with a nerve block in the 4 week period prior to allodynia testing * patients who had been treated with botulinum neurotoxin within the 4 month period prior to allodynia testing
clinical study of ixabepilone administered as a 24 hour infusion in patients with solid malignancies.

Conditions: Solid Malignancies

Summary: the purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for phase ii studies.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of a primary solid tumor * measurable or non-measurable disease * progressive disease * men and women greater or equal to 18 years of age. exclusion criteria: * women of child bearing potential who are not using birth control * women who are pregnant or breast feeding * women with a positive pregnancy test on enrollment * patients with brain metastasis * prior treatment with ixabepilone * known history of human immunodeficiency virus (hiv)
understanding the efficacy of mobile apps as intervention for depression in adults when deployed as part of primary care.

Conditions: Depression; Anxiety; Primary Health Care

Summary: the clinical study is meant to optimize the mobile intervention, to develop a robust implementation plan for the mobile intervention within primary care, and to conduct an effectiveness trial, randomizing 128 participants in order to understand effect on severity of depression and anxiety symptoms, cost-effectiveness, and usability of mobile apps.


Eligibility criteria:
inclusion criteria: * positive screen on phq-9 exclusion criteria: * does not own or use a mobile smart phone
impact of nociception level (nol)-guided remifentanil infusion on intraoperative arterial pressure and vasopressor necessity

Conditions: Head and Neck Surgery; Maxillofacial Surgery

Summary: the aim of this study is to determine if nociception level (nol)-guided remifentanil analgesia, combined with entropy-guided propofol anesthesia, has a significant beneficial effect on the incidence of intraoperative hypotension episodes and/or on vasopressor requirements, during long-lasting major surgeries for high risk patients. the investigator will also investigate the effects of guided anesthesia on postoperative myocardial injury in non-cardiac surgery (mins) and postoperative cognitive dysfunction (pocd), amongst other frequent postoperative complications, in this population.


Eligibility criteria:
inclusion criteria: * age ≥18 * elective high-risk head and neck or maxillo-facial surgery exclusion criteria: * patient refusal * reduced ejection fraction below 40% and heart failure * history of atrial fibrillation, pulmonary embolism, recent cardioversion, recent cardiac ischemic episode, chronic hypotension, chronic kidney insufficiency (serum creatinine \> 1.5) * septic state * baseline heart-rate \ 90 bpm * history of psychiatric disease or medication

Keywords: nociception entropy analgesia goal directed anesthesia therapy (gdat) remifentanil intraoperative hypotension myocardial injury in non-cardiac surgery (mins) postoperative cognitive dysfunction (pocd)
heterogeneity of oral squamous cell carcinoma analysis by single cell rna sequencing

Conditions: Oral Squamous Cell Carcinomas

Summary: the goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scrnaseq in oscc patients.

epidermoid carcinomas of upper aerodigestive tract are the 8th most common cancers in the world. worldwide, this represents more than 500.000 cases per year and 20.000 cases per year in france (statistics 2018-2020). among these cancers, oral squamous cell carcinoma (oscc) are the most common location, leading to significant morbidity and mortality. oscc treatment is based on surgery and/or radiotherapy and/or chemotherapy. immune check point inhibitors (icis) targeting pd-1 have been approved for recurrent and metastasic oscc. however, only 15-20% of these patients are treated thanks to this anti-pd-1. thus, there is a real need to improve the efficacy of icis in the treatment of hnscc. the scrnaseq is a method which allows to study the tumoral heterogeneity, the microenvironment and the dynamic and regulation mecanisms in cells cancer. this technology could improve patient stratification, identify pronostic biomarkers, constitute an important tool in the therapeutical take care and lead to understand tumoral evolution and develop new prevention strategies. the aim of the study is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scrnaseq in oscc patients.

Eligibility criteria:
inclusion criteria: * i1. male or female at least 18 years old. * i2. patient with oscc and undergoing surgery at the centre léon bérard. * i3. patient who has agreed to participate in this research and sign consent. * i4. patient affiliated to a medical insurance. exclusion criteria: * ni1. pregnant or nursing woman. * ni2. contraindication to general anesthesia. * ni3. suspicion of rare tumor of particular histology other than squamous cell carcinoma (sarcoma...). * ni4. patient under curatorial or guardianship or placed under the protection of justice.

Keywords: scrnaseq heterogeneity of all cell population oscc
waiting time. wasting time

Conditions: Pregnancy

Summary: our study's principle purpose is to determine whether decreasing waiting time before being seen for antenatal care increases demand for and use of antenatal care services in mozambique.

this protocol describes a pilot study that will test the impact of a scheduling intervention intended to reduce waiting times for antenatal care. the study will include one intervention health clinic and one control clinic in maputo, mozambique. in the intervention facility women attending antenatal care will be informed that if they return at their scheduled date and time they will be seen within one hour by clinic staff rather than having to wait for an indefinite amount of time before being seen for care. appointment cards will be clipped into anc cards, which collect routine health data and are kept by women at the end of their anc visit. health facility staff will be trained to identify women who return at their scheduled time and to manage patient flow such that scheduled women are received quickly. after the start date of the intervention, all women attending anc at the health facility will be provided a scheduled return date and time window. baseline and endline exit interview surveys will be conducted in both intervention and control facilities to compare changes in waiting time, number of anc visits, and provider satisfaction over the course the study period between clinics.

Eligibility criteria:
inclusion criteria: inclusion criteria for individual study participants enrolled after delivery: 1. women who delivered at the health facility during the weeks of recruitment inclusion criteria for women whose waiting time is measured: 1. women at the health facility to seek care for antenatal care or another reproductive health service (anticipate total enrollment of 800 women) inclusion criteria for the health care provider survey is that the provider 1. have worked in the health facility for at least 6 months 2. the health care worker provides anc as part of their routine duties (anticipate total enrollment of 4 health care workers) exclusion criteria: exclusion criteria for individual study participants enrolled after delivery: 1. women under 18 years of age will be excluded 2. women whose babies die during labor or childbirth from the delivery exit interviews there are no exclusion criteria for the sample of women whose waiting time will be measured there are no exclusion criteria for the health care provider survey
early prediction of qfr in stemi-pharmaco-invasice

Conditions: ST Segment Elevation Myocardial Infarction

Summary: the study intends to provide important data on whether the noval method using quantitative flow ratio could predict microvascular dysfunction.

microvascular dysfunction (mvd) is a serious complication of pci, which happens frequently after stemi and always correlates with a poor prognosis. however, precise and simplified assessment of mvd is difficult, especially in the acute phase of stemi patients. resent studies suggested that ffr could be overestimated when mvd exists. but whether the overestimated value of ffr caused by cmr defined mvo could reflect microcirculation function is still unclear. this study is a retrospective study using stemi patients who underwent pharmaco-invasive strategy as the population. contrast-enhanced cmr was performed 5 days after pci as the reference standard.

Eligibility criteria:
inclusion criteria: * stemi patients treated with revasculation within 12 hours from onset of symptoms to pci time and received cmr 5 days afterwards. stemi was defined as a combination of the following: chest pain for more than 30min, electrocardiographic (ecg) changing with st segment elevation of \>2 mm in at least 2 precordial leads and \>1 mm in limb leads, and abnormal troponin levels or ckmb levels higher than twice the upper limit of normal. * patients underwent successfully pharmaco-invasive strategy with half-dose alteplase. exclusion criteria: * patients with left bundle branch block in the presenting ecg, cardiogenic shock, pci or bypass surgery history. * patients with residual stenosis \<50%. * patients with unqualified coronary angiographic images with problems such as ostial lesion, severe vessel tortuosity and diffuse long lesions.

Keywords: stemi cardiac magnetic resonance pharmaco-invasive
reducing shoulder tip pain following laparoscopic surgery

Conditions: Shoulder Pain; Laparoscopic Surgery

Summary: laparoscopic surgery is becoming a major procedure, owing to smaller incisions, shorter hospitalizations, and less post-operative pain as compared with traditional laparotomies. however, there is marked interindividual variability of post-operative shoulder-tip pain following laparoscopic surgery. the incidence of shoulder pain varies from 35% to 80% and ranges from mild to severe. in some cases, it has been reported to last more than 72 hours after surgery. the hypothesis of post-operative shoulder-tip pain is that carbon dioxide induced phrenic nerve irritation causes referred pain to c4. therefore, the investigators should try to reduce carbon dioxide retention in the pelvic cavity.

this clinical controlled trial is tried to find out the practical and clinical maneuver to reduce post-operative should-tip pain following laparoscopic surgery.

Eligibility criteria:
inclusion criteria: * patients receive benign gynaecological laparoscopic surgery. * american society of anesthesiologists (asa) physical status of patient: classification i-ii exclusion criteria: * the procedure will be required to conversion to laparotomy. * any cardio-vascular diseases.

Keywords: shoulder pain gynecologic laparoscopic surgery nausea vomiting abdominal fullness
safety and pk of repeated doses of irl201104 in healthy volunteers

Conditions: Healthy Volunteer

Summary: the purpose of this study is to assess the safety, tolerability and pharmacokinetics of repeat doses of irl201104 given to healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects age 18 to 65 years of age, and in good health as determined by medical history, physical examination, vital signs, electrocardiogram, and laboratory tests. * female subjects agree to use highly effective contraception or be of non-childbearing potential. * written informed consent must be obtained before any assessment is performed. * able to communicate well with the investigator/designee. exclusion criteria: * any known reaction to study drug or components * concurrent or recent infection or clinically significant conditions that may place subject at risk or interference with absorption, distribution or excretion of drugs * no qtcf interval ≥450 milliseconds, no qrs complex ≥120 milliseconds, at screening * positive test results for hepatitis b surface antigen (hbsag), hepatitis c virus antibodies (hcvab) or human immunodeficiency virus (hiv) 1 and/or -2 antibodies at screening. * excessive use of caffeine-containing beverages * urinary cotinine level indicative of smoking or history or regular use of tobacco- or nicotine containing products within 6 months before screening. * presence or history of drug of alcohol abuse. * positive screen for drugs-of-abuse or cotinine. * blood donation in excess of 500ml within 3 months. * participation in another clinical study with licensed or unlicensed study drug within 3 months of first imp administration. * exposure to more than 4 new chemical entities within 12 months before the first imp administration. * use of live vaccine 28 days before dosing with study drug until telephone follow-up and use of killed vaccine (including covid-19 vaccine) 14 days before dosing with study drug until telephone follow-up.